Resilience Stock

resilience.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $2.03B

Resilience is a biomanufacturing business focusing on pharmaceuticals. Their team is focused on producing complex solutions such as gene therapies, vaccines, and cell therapies. Resilience was founded in 2020 by Drew Oetting, Patrick Yang Ph.D, Sandesh Mahatme, and Rahul Singhvi Ph.D and is headquartered in La Jolla, CA.

Register for Details

For more details on financing and valuation for Resilience, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Resilience.

Register Today


Management Team

Syed Husain
Chief Commercial Officer
Elliot Menschik Ph.D
Chief Digital Officer
Spencer Fisk
Chief Technology Officer
Ori Solomon JD
Chief Legal Officer, General Counsel
Duane Avant
Chief Quality Officer
Viet Nguyen
Chief Manufacturing Officer
Rahul Singhvi Ph.D
Co-Founder, Chief Executive Officer & Board Member
Sandesh Mahatme
Co-Founder, President, Chief Financial Officer & Chief Operating Officer

Board Members

Scott Gottlieb MD
New Enterprise Associates
Susan Desmond-Hellmann MD

Other companies like Resilience in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

On the defense: Resilience bags $410m US Gov contract
The $410 million long-term funding agreement with the US Department of Defense (DoD), in collaboration with the US International Development Finance Corporation (DFC), aims to support Resilience’s capabilities and strengthen domestic bioproduction.
As US plots biomanufacturing boost, National Resilience nets $410M loan from Defense Department
Amid a spate of drug production pledges from the White House, U.S.-based manufacturer National Resilience has scored new government financing to keep its mission running for the long haul.
AstraZeneca to sell Ohio site to biotech firm Resilience
AstraZeneca is selling its West Chester manufacturing site in Ohio in the United States to biomanufacturing company National Resilience Inc, the company said on Tuesday.
Updated on: Oct 2, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.